Forest Labs Starts Patent Battle Over Beta-Blocker

Law360, New York (March 14, 2012, 3:05 PM EDT) -- Pharmaceutical maker Forest Laboratories Inc. on Wednesday accused a slew of generics makers of violating its patent for beta-blocker Bystolic in a complaint filed in Delaware federal court.

The New York-based company claims the defendants — Amerigen Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Hetero Labs Ltd., Torrent Pharmaceuticals Ltd., Watson Pharmaceuticals Inc. and their subsidiaries — violated the patent for the blood pressure drug by filling abbreviated new drug applications seeking permission to begin production of generic versions.

The patent-in-suit is U.S. Patent Number 6,545,040, titled “Method...
To view the full article, register now.